Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $400,750.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the transaction, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This trade represents a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, August 10th, Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock. The stock was sold at an average price of $27.98, for a total transaction of $524,625.00.
• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $22.81 on Friday. The firm has a 50 day simple moving average of $25.89 and a 200-day simple moving average of $22.98. Bicara Therapeutics Inc. has a 1-year low of $10.30 and a 1-year high of $30.99. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -7.36 and a beta of -0.82.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting the consensus estimate of ($0.82). On average, equities analysts expect that Bicara Therapeutics Inc. will post -3.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on BCAX. Citigroup reaffirmed a “market outperform” rating on shares of Bicara Therapeutics in a research report on Friday, August 21st. Wedbush lifted their price target on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Mizuho boosted their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.64.

Institutional Trading of Bicara Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of BCAX. AQR Capital Management LLC acquired a new position in Bicara Therapeutics during the first quarter valued at approximately $248,000. Woodline Partners LP increased its position in shares of Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after acquiring an additional 72,998 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Bicara Therapeutics by 26.0% in the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after acquiring an additional 5,664 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for solid tumors. The company uses a proprietary bifunctional antibody platform designed to target tumor cells while modifying the surrounding tumor microenvironment, which may help improve the activity of cancer immunotherapies.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to block epidermal growth factor receptor (EGFR) signaling and inhibit transforming growth factor beta (TGF-β), two pathways associated with tumor growth and immune suppression.